The GATA4, 5 and 6 subfamily of transcription factors are potent transactivators of transcription expressed within the precardiac mesoderm. However, little is known of the immediate downstream targets of GATA-factor regulation during the earliest stages of cardiogenesis. Using the P19-CL6 embryonal carcinoma (EC) cell line as an in vitro model of cardiogenesis, we show that GATA6 is the most abundantly expressed of the GATA factors in presumptive cardiac cells. Consequently, we performed a microarray screen comparing mRNA from control EC cells, early in the cardiac differentiation pathway, with those in which GATA6 had been overexpressed. These studies identified 103 genes whose expression changed significantly and this was verified in a representative array of these genes by real-time RT-PCR. We show that early cardiac expression of one of these genes, Wnt2, mirrors that of GATA6 in vitro and in vivo. In addition, its upregulation by GATA6 in differentiating EC cells is mediated by the direct binding of GATA-factor(s) to the cognate Wnt2 promoter, suggesting Wnt2 is an immediate downstream target of GATAfactor regulation during early cardiogenesis. q
Introduction
The molecular basis of vertebrate cardiogenesis is increasingly becoming understood. The formation of a multi-chambered, beating heart requires the activation of a cascade of transcription factors under tight temporal and spatial control and congenital heart defects can result if this ordered arrangement is perturbed (for review see (Bruneau, 2002) ). Many of these regulatory factors have been identified and cloned and it has emerged that the GATA4, 5 and 6 sub-family of transcription factors, which display partially overlapping expression domains in heart and some endodermally derived tissues play an integral role in cardiogenesis (for reviews see (Molkentin, 2000; Patient and Mcghee, 2002; Peterkin et al., 2005) ). Studies of cis-regulatory elements have demonstrated important roles of GATA factors in promoting the expression of many myocardial genes, including a-and b-myosin heavy chain (a-and b-MHC), cardiac troponin C, atrial natriuretic peptide (ANF) and brain natriuretic peptide (BNP) . GATA4, 5 and 6 are co-expressed within the prospective cardiac mesoderm from the earliest time of its specification Peterkin et al., 2005) . However, in the mouse, the expression pattern of GATA5 subsequently diverges from that of GATA4 and 6: GATA5 becoming restricted to the endocardium , whereas GATA4 and 6 are expressed within the myocardium throughout development and adult life (Arceci et al., 1993; Kelley et al., 1993; Heikinheimo et al., 1994) .
Given the high degree of homology within the DNA binding domains of GATA-family members (Laverriere et al., 1994; Jiang and Evans, 1996) , a degree of functional redundancy has been suggested within domains in which different family members are co-expressed. This is particularly relevant in the case of GATA4 and 6 in the developing heart, where the expression patterns overlap both temporally and spatially.
Targeted disruption of GATA4 or 6 expression in the mouse, however, resulted in very different phenotypes, both of which are embryonic lethal and correspondingly associated with ventral closure or early endodermal defects (Kuo et al., 1997; Molkentin et al., 1997; Morrisey et al., 1998; Koutsourakis et al., 1999) . Thus, in at least some cases, both GATA4 and 6 have specific, crucial roles in development, and cannot compensate for each others' loss.
Partly because of the early lethality of the null mutants, the specific functions of GATA4 and 6 within the mammalian heart have been difficult to assess. Nonetheless GATA4 null embryos were shown to develop splanchnic mesoderm, which differentiated into cardiomyocytes expressing contractile proteins (Kuo et al., 1997; Molkentin et al., 1997) . Similarly, GATA6 null ES cells differentiated into cardiomyocytes both in embryoid bodies in vitro, and in chimaeric mice, where they contributed to heart structures up to at least E10.5 . More recently, the early extraembryonic endoderm deficiencies of GATA4 and 6 null embryos have been rescued by tetraploid embryo complementation to support their gastrulation. The GATA4 K/K rescued embryos arrested by E10, and displayed heart morphogenic defects including disrupted looping and septation, and a loss of the proepicardium (Watt et al., 2004) . The rescued GATA6
K/K embryos similarly survived only until E10.5 and were consistently smaller than control embryos, possibly due to impaired cardiovascular function, and the extent of ventricular trabeculation was in some cases reduced (Zhao et al., 2005) . In both the GATA4 K/K and GATA6 K/K embryos, however, no overt disruption of cardiac GATA-dependent gene expression was observed. GATA5 null embryos, by contrast, were viable and their hearts developed normally . A requirement for a specific GATA-binding activity in the differentiation of the myocardium per se has therefore not been demonstrated in mammals by contrast to Xenopus and zebrafish (Reiter et al., 1999; Peterkin et al., 2003) . Thus, there appear to be species differences in the requirement for a specific GATA-binding activity to effect cardiomyocyte differentiation.
While a large number of late cardiac-expressed structural genes have now been shown to be regulated by GATAfactors, little is known of the very earliest targets of GATA regulation in differentiating cardiomyoctes. Very early molecular events in mammalian cardiogenesis are currently difficult to elucidate using in vivo systems. Consequently, we (Brewer et al., 2005) and others (see (Anisimov et al., 2002) and references therein) have used the P19 embryonal carcinoma (EC) cell line as an in vitro mammalian model system for cardiomyocyte differentiation. Both serial analysis of gene expression (SAGE) (Anisimov et al., 2002) and microarray (Peng et al., 2002) analyses performed on P19 cells before and after differentiation have validated this system as a model of cardiogenesis. We have here utilised a clonal derivative, P19-CL6, which can be induced to differentiate highly efficiently (typicallyO80%) along the cardiogenic pathway (Habara-Ohkubo, 1996) . We have shown previously that overexpression of GATA4 or 6 early during the cardiac differentiation pathway, is sufficient to elicit premature expression of Nkx2.5, an early marker of precardiac mesoderm (Brewer et al., 2005) . We show here that of the three cardiac-expressed GATA-family members, GATA6 is the most highly expressed, and thus potentially the most functionally significant, within P19-CL6 cells at this early stage of cardiac differentiation. We have therefore undertaken a microarray analysis comparing P19-CL6 cells overexpressing GATA6 with control cells, in order to identify putative downstream targets of GATA6 (and potentially other GATA-binding factors) during cardiogenesis. We describe here the results of this screen and provide expression and functional promoter data which strongly suggest that one of the up-regulated genes identified, Wnt2, is a direct downstream target of GATA6 both in differentiating P19-CL6 cells and in vivo. Moreover the overlapping patterns of expression of GATA6 and Wnt2 within E9.5 mouse embryos suggest that both genes may have a prominent role in the formation of the inflow tract of the developing heart and adjacent septum transversum.
Results

Identification of genes regulated by GATA6 during cardiac differentiation
During a 10-day time course of DMSO-mediated differentiation of P19-CL6 cells to beating cardiomyocytes, we show here by quantitative RT-PCR (qPCR) that the levels of GATA4, 5 and 6 transcripts all increase significantly (O50-fold; Fig. 1A-C) . In agreement with our previous findings, we show that by day 4 of induction the levels of GATA4 and 6 mRNAs are already elevated w10-and w16-fold, respectively, relative to levels in undifferentiated cells (Fig. 1A and C and (Brewer et al., 2005)) . By contrast the level of GATA5 expression was found not to increase until after this early stage of differentiation (Fig. 1B) . We have also shown previously that it is possible to activate transcription of Nkx2.5 prematurely in this system, by overexpressing GATA4 or 6 Fig. 2 . Identification of putative GATA6 targets by microarray analyses. (A) Two microarray chips were used to analyse the gene expression profiles of each of two biological replicates of control P19-CL6 cell samples, and one chip was used to analyse a GATA6 overexpressing cell sample. The numbers on the arrows indicate the number of transcripts that differ by 2-fold or more in their expression levels between the corresponding microarrays as indicated. The number in the square brackets indicates the consensus number of transcripts whose expression was found to be regulated by GATA6. This consensus of 123 distinct transcripts represents 103 unique genes. (B) Classification of genes altered by overexpression of GATA6 according to their main functions. Brewer et al., 2005) with GATA6 being the more potent transactivator. These data suggest that the level of a GATAbinding factor(s) is critical in determining the timing of cardiomyocyte differentiation. We have determined the relative levels of endogenous GATA4, 5 and 6 at this stage (day 4 of induction), and show that GATA6 is the most highly expressed factor, being w4-fold more abundant than GATA4 and O100-fold more abundant than GATA5 at the mRNA level (Fig. 1D ). GATA6 is thus the most abundant of the three factors at this very early stage of differentiation, the strongest transactivator of the Nkx 2.5 promoter and is the most significantly up-regulated (Fig. 1C) . Thus, GATA6 may be the GATA-binding factor, which is the most functionally significant at this stage of cardiac differentiation, at least in this model system. To identify other potential targets of GATA-binding activity we performed a microarray screen in which we compared mRNAs harvested from P19-CL6 cells at day 4 of induction, which had been transfected with either a GATA6-expressing plasmid or the control vector. In order to enrich for direct targets, differentiating P19-CL6 cells were subjected to GATA6 overexpression for just 24 hours. The level of GATA6 overexpression, at the RNA level, was calculated by qPCR to be w300-fold and was shown to be functionally successful as it resulted in w5-fold increase in Nkx2.5 expression (data not shown); thus the RNAs from these cultures were considered suitable for further analyses.
We screened two Mouse Expression Set 430A chips (Affymetrix) using biological duplicate control RNAs, to assess the background variability in both the biological system and the technical analyses. As shown in Fig. 2A , of the 22,690 probe sets screened, only nine showed a relative difference in expression between the two control samples of R2-fold, suggesting little inherent variability between duplicate assays. A single chip was used to assess the transcriptome of the GATA6-overexpessing P19-CL6 cells: this identified 123 transcripts, corresponding to 103 unique genes which were Characterised unique genes, which were activated or repressed R2-fold by GATA6 overexpression, are classified according to their primary functions.
activated or repressed R2-fold, by comparison to both control chips. Of these, 68% were up-regulated and 32% were downregulated. A detailed list of the differentially expressed genes and a classification of their primary functions is shown (Table 1 , Fig. 2B ). It should be noted that the small number of chips used in our array screen precludes any statistical analyses that would permit significance evaluation of smaller changes in gene expression (i.e. less than 2-fold). Thus, the data set presented here probably underestimates the number of GATA6-responsive genes.
qPCR analysis of selected genes up-or down-regulated by GATA6
Of the relatively small number of up-regulated genes identified in our screen, some are known to be involved in the regulation of heart development, such as BMP4, Runx1, Eomes and Msx2, (Abdelwahid et al., 2001; Gattenlohner et al., 2003; Ryan et al., 2004) . In addition, many of the upregulated genes are known to be expressed within the developing heart, although their functions have yet to be elucidated, such as Wnt2, Nr0b1 and Gas6 (Monkley et al., 1996; Bae et al., 1996; Rees et al., 1999) . However, in the case of a number of the other identified genes, such as Asb4, Cdc42ep5 and Efnb1, expression in the early heart has not hitherto been examined. To validate the microarray analyses, we examined the mRNA levels of a representative selection of these up-regulated genes by qPCR, including several which are known to be cardiac-expressed. We have concentrated on genes encoding transcription factors and molecules involved in signal transduction, since these are most likely to be effectors of differentiation. The relative changes in expression of these genes, dependent upon GATA6 overexpression, have been quantitated. RNA from biological triplicate samples, comprising day 4 induced cells which had been transfected at day 3 with either the GATA6-expressing plasmid or the control vector (and including the samples used for the microarray analyses) were analysed. As shown in Fig. 3 , GATA6 overexpression effected an increase in the relative expression levels of all these genes, as predicted by the chip analyses. The degree of upregulation, however, varied greatly between the different genes. Although in most cases an increase in mRNA levels of !10-fold was observed, substantially greater increases were detected for Wnt2, Nr0b1 and Runx1. In particular, we found an w80-fold increase in Wnt2 expression upon forced expression of GATA6.
We also confirmed and quantitated the changes in expression of selected down-regulated genes identified in the screen. Again, qPCR data verified the differential expression of these 'repressed' genes, and in all cases the mRNA levels were found to decrease by at least 40% (Fig. 3) . Clearly therefore, the microarray analyses have identified bona fide differentially expressed genes. An indication of the degree of variability in the consequences . C and D are enlargements of A and B, respectively, demonstrating expression in cardiac and cardiacassociated domains. Note that while expression can be detected, particularly for GATA6 in the atria (A) and ventricles (V), strongest labelling is associated with the septum transversum (white arrows). (E, F) Cryostat sections of the E9.5 mouse embryo shown in B. F is a higher magnification, serial section of E. In addition to Wnt2 labelling within the mesenchyme of the septum transversum (white asterisks), expression can also be seen within the walls of the primary atrial tube at the venous pole (black arrows). In F, dashed yellow lines mark the division between these two expression domains.
of forced expression of GATA6 is given in the standard errors of the means depicted in Fig. 3 . Thus, GATA6 overexpression in inducing P19-CL6 cells was shown here to result in transcriptional changes that were both qualitatively and quantitatively reproducible.
The expression profile of Wnt2 mirrors that of GATA6 in differentiating cardiomyocytes
The magnitude of the upregulation of expression of the Wnt2 gene (approximately 80-fold) would strongly suggest that this may represent a physiologically significant downstream target of GATA6 within the differentiating P19-CL6 cells. Moreover, during mouse development, Wnt2 has been shown to be first expressed specifically within the precardiac mesoderm of the heart primordia of E7.5 mouse embryos (Monkley et al., 1996) , in a similar pattern to that reported for GATA6 . To investigate further the relationship between GATA6 and Wnt2 expression during cardiomyocyte differentiation, we compared the expression profiles of the two genes in vitro, during a time course of P19-CL6 cardiogenic induction. As shown in Fig. 4A , Wnt2 mRNA levels were found to increase significantly between days 2 and 4, and to continue to accumulate until day 10. This pattern shows a marked similarity with that of the expression of GATA6 (Fig. 4B) . Thus both the spatial expression patterns of Wnt2 in vivo, and the temporal changes in Wnt2 expression during cardiomyocyte differentiation in vitro, closely mirror those of GATA6.
GATA6 and Wnt2 expression domains overlap in E9.5 embryos
Subsequent to mouse E7.5, the heart precursor cells Fig. 6 . GATA6 can bind directly to sites within the Wnt2 proximal promoter. (A) Schematic alignment of homologous genomic sequence upstream of mouse, rat, chimpanzee and human Wnt2 coding sequence. Potential GATA-binding sites (site 1 and site 2) that are conserved between these species are shown as open boxes. (B) EMSA using a known radiolabelled GATA-binding dsoligonucleotide probe aG2, and Cos7, or GATA6-overexpressing Cos7 nuclear cell extracts, with or without a 200-fold excess of unlabelled probe as competitor. (C and D) EMSAs using radiolabelled probes corresponding to site 1 or site 2, respectively within the mouse Wnt2 promoter, and GATA6-overexpressing nuclear cell extract, with or without a 200-fold excess of unlabelled oligonucleotide probe competitor as indicated.
continue to differentiate, as the paired cardiac primordia migrate to the ventral midline and fuse to form a linear tube. To determine the extent of co-localisation between GATA6 and Wnt2 in cardiac and cardiac-associated expression domains at a later stage, after tube formation, we performed whole-mount in situ hybridisation on mouse embryos at E9.5. By this stage, the primordia of most organ systems are established and while heart looping is complete, extensive re-modelling is still taking place (Kaufman and Bard, 1999) . The expression domains of GATA6 mRNA and protein have been well documented in mouse development (Brewer et al., 1999 (Brewer et al., , 2002 Nemer and Nemer, 2003) . By contrast, there is less detailed information, and no analysis of sectioned material, on Wnt2 expression in the heart at this later stage. We found here, by analysis of whole-mount embryos, that the expression domains of GATA6 and Wnt2 within the heart region were essentially equivalent. Consistent with previous studies on both GATA6 protein (Nemer and Nemer, 2003) and Wnt2 mRNA (Monkley et al., 1996) , the major staining was apparent within the septum transversum, with much weaker staining seen in atrial and ventricular myocardium (Fig. 5A,B) . Sectioned whole-mount embryos, labelled for Wnt2 expression, show that in addition to the septum transversum, expression extends to the venous channels as they drain into the right component of the common atrial chamber (Fig. 5E,F) . This domain has also previously been recognised as a site of GATA6 protein expression (Nemer and Nemer, 2003) but represents a restriction of the earlier, broader domain of Wnt2 in E8 embryos, where expression extends throughout the right and left horns of the sinus venosus (Monkley et al., 1996) . Thus, GATA6 and Wnt2 are initially both expressed in the precardiac mesoderm, and this overlapping pattern of expression persists at later stages in a narrow domain at the venous pole of the developing heart, together with the related septum traversum.
2.5. Two highly conserved GATA-sites are located within the Wnt2 proximal promoter
We next sought to determine whether GATA6 can act to upregulate Wnt2 expression by binding directly to a cis-acting regulatory motif(s) within the Wnt2 gene locus. The putative transcriptional CAP site, and hence proximal promoter region of the human Wnt2 gene has been identified (Katoh, 2003) . We aligned the homologous 5 0 flanking regions upstream of the coding regions of human, chimpanzee, rat and mouse Wnt2 genes, to look for conserved and therefore potentially important regulatory regions. A database search of potential transcriptional binding sites revealed several consensus canonical GATA-factor binding sites; A/T GATA A/G (Evans and Felsenfeld, 1989) , upstream and proximal to the mouse Wnt2 translational start site. Two of these sites, at positions K1144 to K1149, and K162 to K167 relative to the mouse translational start site, were found to be entirely conserved, suggesting functional significance. In each case the conserved GATA consensus sequence is located within an extended region of high homology, again indicating functional importance (Fig. 6A) . The more distal site (site 1) lies approximately 850 bp upstream of the (presumptive) CAP site, while the more proximal site, at K162/K167 (site 2) is situated within the putative 5 0 untranslated region (UTR).
GATA6 binds directly to the Wnt2 promoter in vitro
Direct binding of GATA6 to the putative GATA sites within the Wnt2 promoter was investigated using EMSA. Initially, a radiolabelled oligonuleotide containing a known GATAbinding site, aG2, was incubated in the presence of nuclear cell extract isolated from either normal Cos7 cells, (which do not contain GATA-binding activity (Yokoyama et al., 2003) ), or GATA6-transfected Cos7 cells. As shown in Fig. 6B , the GATA6-expressing Cos7 cell extract contains binding activity not apparent in normal cells. Specificity was demonstrated by competition with a 200-fold excess of unlabelled oligonucleotide, which resulted in a large reduction of the retarded complex. We therefore used these cell extracts, from the GATA6 transfected Cos7 cells to investigate GATA6 binding (mutated GATA-binding site 2) at day 3 of induction, together with either pLINK or the GATA6 expression vector pLINK-G6, and the co-transfected control plasmid pRL-SV40-d238, and assessed at day 4. The results presented represent the fold increase in the relative luciferase activity resulting from each test reporter construct, upon GATA6 overexpression.
to the Wnt2 promoter. Two separate oligonucleotides, termed Wnt2 site 1 and Wnt2 site 2, comprising the two putative GATA-binding sites were radiolabelled and incubated with the GATA6-containing extract. In each case we detected a complex of an equivalent mobility to that shown in panel B (see Fig. 6 , lane 2, C,D). In both cases the complex could be efficiently competed by the addition of an excess of unlabelled oligonucleotide (lane 3, C,D), or the known GATA-binding site aG2 (lane 4). By contrast, addition of an excess of either an oligonucleotide in which the GATA site had been specifically mutated (mut; lane 5, C,D), or an Sp1 binding site (lane 6), both failed to inhibit formation of the complex. The addition of extract isolated from normal Cos7 cells did not result in a complex of this mobility in either case (data not shown). These data therefore clearly demonstrate that GATA6 can bind directly to at least two sites within the proximal promoter region of the mouse Wnt2 gene.
2.7. The activity of the Wnt2 promoter fragment mimics that of the endogenous gene during early cardiac differentiation A 1.33 kb mouse genomic fragment comprising approximately 1 kb of upstream, putative promoter sequences together with approximately 300 bp of 5 0 UTR were cloned into the luciferase reporter vector, pGL3-Basic (Promega), to generate Wnt2-pGL3. This fragment is shown in Fig. 6A , and includes both conserved GATA-factor binding sites. Wnt2-pGL3 was transfected into P19-CL6 cells at different stages of their early induction (up to day 6), to assess the ability of the promoter fragment to drive luciferase expression, relative to that effected by the co-transfected reference plasmid, pRL-SV40-d238. As shown in Fig. 7A , the activity of the promoter fragment during this early time course of cardiac differentiation qualatitively mimics the temporal expression of that of the endogenous gene (Fig. 4A ). In particular, activity increases significantly between day 2 and day 4 of induction, as does expression of both endogenous GATA6 and Wnt2 (Fig. 4A,B) . After day 6, induced P19-CL6 cells become increasingly hard to transfect, thus the activity of the promoter fragment was not assessed at later time points.
The regulation of mouse Wnt2 expression by GATA6 is mediated in part by a canonical GATA-factor binding site
To determine the functional significance of the GATAbinding sites within the 1.33 kb Wnt2 proximal promoter region, we mutated each site separately. The sequence 5 0 -TGATAA-3 0 , within the more upstream site (site 1; Fig. 6A ) was mutated to 5 0 -TTTAAA-3 0 ; a sequence which cannot bind GATA factors (Ko and Engel, 1993) , to generate Wnt2mut1-pGL3. Similarly, the 'reverse' GATA-binding sequence within the more downstream site (site 2; Fig. 6A ), 5 0 -TTATCA-3 0 , was mutated to 5 0 -TTTAAA-3 0 , to generate Wnt2mut2-pGL3. We assessed the ability of the wild type and both mutated promoter fragments to mediate an increase in reporter activity, dependent upon GATA6 overexpression. P19-CL6 cells were transfected at day 3 of induction with Wnt2-pGL3, Wnt2mut1-pGL3 or Wnt2mut2-pGL3, together with the GATA6 expressing construct, pLINK-G6, or empty vector control, and the co-transfected reference plasmid. pGL3-Basic was also transfected, with and without GATA6 as a negative control. Relative luciferase activity resulting from the reporter constructs was analyzed after 24 hours incubation, and data are expressed here as the fold-increase in activity of each promoter fragment, upon GATA6 overexpression. Thus, GATA6 overexpression resulted in an w12-fold increase in the activity of the 'promoterless' pGL3-Basic control plasmid (Fig. 7B) . Expression from the wild-type Wnt2 promoter fragment, however, increasedO120-fold upon GATA6 overexpression. Perhaps surprisingly, specific mutation of the more distal GATA-factor binding site (site 1) resulted only in a small, and not significant reduction in the ability of GATA6 to transactivate the promoter fragment. However mutation of the more proximal GATA-binding site, within the 5 0 UTR sequences (site 2), resulted in a highly significant decrease (approximately 58%) in the ability of GATA6 to transactivate the Wnt2 promoter fragment. It is thus clear that this more downstream site can both bind to GATA6 directly and mediate an upregulation in Wnt2 transcription that is dependent upon GATA6 expression. Mutation of both sites resulted in a decrease in GATA-dependent transactivation similar to that observed for site 2 alone (data not shown), again suggesting that the more distal site, while capable of binding GATA6 in vitro, may not be mediating the promoter activation observed in these experiments. It should be noted that mutation of site 2 did not result in a complete abolishment of GATA6-dependent promoter activation, suggesting the presence of other, unidentified GATA-binding sites within this fragment. Alternatively other, indirect mechanisms of GATA-mediated transactivation may also contribute. Nonetheless, these data demonstrate that the direct binding of GATA6 to (at least) one cognate site within the Wnt2 proximal promoter can activate Wnt2 transcription in precardiac cells.
Discussion
Identified genes are genuine downstream targets of GATA6
The aim of this study was to identify direct downstream targets of GATA-binding activity during early stages of cardiomyoctye differentiation in order to understand further the complex transcriptional cascades, which underlie cardiogenesis. The P19 EC cell system has been shown previously by a broad range of criteria to be a useful model of cardiogenesis (Anisimov et al., 2002; Peng et al., 2002; van der Heyden and Defize, 2003; Ohtsu et al., 2005) . We have performed gene chip array analyses within early differentiating P19-CL6 cells, to assess the transcriptional consequences of overexpression of GATA6.
We have identified genes whose expression was found to be altered significantly by forced expression of GATA6, between the 3rd and 4th day of DMSO-stimulated induction and in all cases tested, the microarray data were confirmed by qPCR. Thus, the list of genes identified is likely to represent bona fide downstream targets of GATA6 regulation. The list, however, is not comprehensive. For example, although by qPCR we had shown Nkx2.5 to be significantly up-regulated in the RNA samples used for the gene chip analyses, it was undetected in the microarray screen, presumably because the levels were too low. In addition, the degree of upregulation determined by the microarray screen was not always confirmed by qPCR. This difference in the quantitation of changes in relative abundance between the two techniques, has been noted previously (Rajeevan et al., 2001) , and may be accounted for in part, by cross-hybridization of different members of gene families in microarray screens. It should also be noted, that a possible limitation of such a gain-of-function microarray approach is that artificial elevation of a transcription factor to nonphysiological levels may result in binding to low affinity sites which are not normally occupied, and yield misleading results. Thus, other lines of evidence will always be required to demonstrate a functional relationship between GATA6 and any up-regulated gene identified in this screen.
In the case of the down-regulated genes, it is unclear as to whether the regulation observed can be mediated by direct GATA-binding to cis-acting regulatory genomic regions. There is, at present, no evidence that GATA6 can function as a direct transcriptional repressor. Nonetheless GATA1 has been shown to function as a direct repressor of GATA2 transcription (Grass et al., 2003) , and negative cross regulation of GATA6 by GATA4 has also been suggested (Kuo et al., 1997) .
Identified genes are involved in cardiogenesis
During mouse embryogenesis, GATA4, 5 and 6 are also known to be expressed in primitive endoderm and both GATA6 and 4 have been shown to enhance differentiation of extraembryonic and visceral endoderm from embryonic stem cells (Fujikura et al., 2002) . Although enriched for cardiac lineages, P19-CL6 cells are by their nature heterogeneous, and thus we cannot rule out the possibility that some of the targets of GATA6 identified here may reflect a role in endodermal differentiation. Nonetheless, some of the genes identified in our microarray screen are already known or are suspected to be involved in early heart development. Furthermore a complementary microarray analysis of in vivo cardiac progenitors identified only 28 transcripts which were enriched in the cardiac population including neuropilin-1, glycogenin-1 and Fli1 (Masino et al., 2004) ; all genes identified in our study. Interestingly, increased expression of the first two examples was not found in adult cardiomyocytes suggesting that their roles are specific to early stages of cardiogenesis. Thus, we believe that the genes identified in our microarray screen will prove a valuable basis for future studies of molecular mechanisms which effect cardiac differentiation.
Wnt genes in cardiogenesis
The signalling molecule Wnt2 was identified in our microarray screen, and of all genes tested was found by qPCR to be the most substantially up-regulated. The magnitude of this transactivation (w80-fold), together with the temporal and spatial co-expression of GATA6 and Wnt2 in vitro and in vivo therefore, strongly suggest Wnt2 to be a target of GATA6 under normal physiological conditions. Further, we demonstrated that Wnt2 is a probable direct target of GATAbinding by a combination of sequence analyses, EMSAs and promoter transactivation assays. We acknowledge however that while compelling, these data do not constitute a formal proof of direct action of GATA6 on the Wnt2 promoter, as this would require additional in vivo studies, such as chromatin immunoprecipitation analyses on precardiac mesodermal cells.
The role of Wnt genes in cardiac development has been investigated in a wide range of species. In Xenopus, mouse and chick (Eisenberg and Eisenberg, 2001; Pandur et al., 2002) , Wnt11 promotes cardiogenesis, while Wnt3A and 8 have to be inhibited for heart formation to proceed in the chick (Marvin et al., 2001) or Xenopus (Schneider and Mercola, 2001) . By contrast, Wnt3A has been shown to promote cardiogenesis in P19-CL6 cells and mouse embryoid bodies (EBs) which may reflect species differences in the roles of Wnt proteins in early cardiogenesis or differences in the stages of differentiation at which the cells were studied (Nakamura et al., 2003; Ueno et al., 2005) . Wnt2 is known to be expressed in the early mouse heart (Monkley et al., 1996) , however, its cardiac function remains to be elucidated.
The requirements for different Wnt activities in cardiogenesis appear to involve different transduction mechanisms. Thus, the inhibitory actions of Wnt3A and 8 in amphibia appear to operate via a canonical, b-catenin dependent pathway (Schneider and Mercola, 2001 ) while the stimulatory action of Wnt11 seems mediated via non-canonical, JNK-and PKCdependent signalling (Pandur et al., 2002) . The reported positive requirement for Wnt3A in mammalian cardiomyocyte differentiation has also been shown to involve canonical signalling (Nakamura et al., 2003; Ueno et al., 2005) . Wnt2 signalling has been shown to be mediated by both canonical and non-canonical pathways in different systems (Karasawa et al., 2002; Le Floch et al., 2005) , and we have no knowledge at present as to the mechanisms whereby Wnt2 signals are transduced in early cardiogenesis.
In vivo, GATA4, 5 and 6, together with Wnt2 are all highly expressed in precardiac mesoderm (Heikinheimo et al., 1994; Monkley et al., 1996; Morrisey et al., 1997; MacNeill et al., 2000; Nemer and Nemer, 2003) . Later during development the expression patterns of Wnt2 and GATA6 overlap, and low levels of expression of both genes persist in the early embryonic myocardium consistent with previous studies (Fig. 5 and (Monkley et al., 1996; Nemer and Nemer, 2003) ). However the major expression domains of Wnt2 in E9.5 mouse embryos are in the septum transversum and junction of the atrial chamber to the sinus venosus. The former has previously been reported to be among the major expression domains of GATA6 and 4 (Nemer and Nemer, 2003) . We have performed qPCR analyses of the heart regions of E9.5 mouse embryos, and shown both GATA4 and 6 to be equally abundant, and approximately 2-fold more highly expressed than GATA5 (data not shown).
The role of these genes at the venous pole of the embryonic heart is unclear but the remodelling of the venous channels as they drain into the atria is a subject undergoing much debate at present (Anderson, 2005) and we are currently investigating the role of Wnt2 and GATA-factors in this process. Wnt2 null mice displayed runting and approximately 50% died perinatally due, at least in part, to placental defects. However, impaired cardiac function during development could clearly also contribute to such a phenotype. Moreover, although the gross anatomy of the hearts appeared normal within Wnt2 K/K mice that survived to adulthood, anatomically subtle but physiologically important defects could have been undetected (Monkley et al., 1996) .
Specificity of GATA-factor roles
Loss of function experiments suggest some functional redundancy in the roles of GATA4, 5 and 6 to effect cardiomyocyte differentiation in mammalian systems Watt et al., 2004; Zhao et al., 2005) . Accordingly, where studied, we have found the genes identified in our GATA6 overexpression screen to be similarly up-regulated by forced expression of GATA4 (data not shown). Other in vitro studies have also shown a lack of specificity in the ability of different GATA-binding factors to transactivate individual genes (McBride and Nemer, 2001; Divine et al., 2004) .
Antisense studies in postnatal rat cardiomyocytes have demonstrated some preferential regulation of a-and b-MHC by GATA4, but equivalent down-regulation of ANF and BNP transcription in cardiomyocytes lacking GATA4 or 6 . We have also begun experiments to inhibit expression of specific GATA-binding factors in the differentiating P19-CL6 cells using small interfering RNAs (siRNAs), and our preliminary data demonstrate only a modest reduction in Wnt2 expression upon silencing of GATA4 or 6 (data not shown).
Beyond the initiation of cardiogenesis and the progressive differentiation of precardiac cells, the effect of loss of GATA4 function specifically in the myocardium of mice at early and late time points in cardiac morphogenesis using Cre/loxP technology has demonstrated specific roles for GATA4 in regulating the morphogenesis of the right ventricle and septation (Zeisberg et al., 2005) . The consequences of ablating GATA6 expression specifically in the myocardium of mice have not thus far been reported. Differential expression of GATA4 and 6 within individual sub-populations of cardiomyocytes within the developing heart (Nemer and Nemer, 2003) may account for role specificity. Accordingly we are currently investigating the expression patterns of Wnt2 and specific GATA-factors within individual cells of the venous pole of the embryonic heart.
In summary, we have identified Wnt2 as a direct target of GATA-factor(s) regulation during cardiomyocyte differentiation and have thus established a link between two families of genes known to have major roles in early cardiogenesis. In addition to both genes being expressed within the precardiac mesoderm, at later stages, high levels of Wnt2 expression coincide with those of GATA6 and other GATA factors at the venous pole of the heart and the adjoining septum transversum. The functional consequences of both of these observations are currently under investigation.
Experimental procedures
Cell culture
P19-CL6 cells were a kind gift of Issei Komuro and were cultured and induced to differentiate along cardiac lineages as previously described (Hosoda et al., 2001; Brewer et al., 2005) . Cos7 cells were obtained from the ECACC and cultured according to supplier's recommendations.
Cell transfection
Transfections of P19-CL6 or Cos7 cells were performed using Lipofectamine 2000 (Invitrogen) according to manufacturer's recommendations. Cells were transfected using 8 mg total DNA for 6 cm dishes or 2 mg total DNA for each well of a 24 well plate following manufacturer's instructions. Cells were incubated for 24 h prior to assessment.
Transfection constructs
The full-length GATA6 expression construct, pLINK-G6, was generated by cloning the complete mouse GATA6 coding sequence into pEF pLINK II 4.9 (pLINK) as described previously (Brewer et al., 2005 This fragment, corresponding to sequences K1330 to K4, relative to the Wnt2 translational start site (see Fig. 6A ), was cloned into the XhoI/HindIII sites of the luciferase reporter vector, pGL3-Basic (Promega), to generate Wnt2-pGL3.
Site specific mutations of the potential GATA-binding sites at K1144/K 1149, (site 1, TGATAA to TTTAAA), or K162/K167 (site 2, TTATCA to TTTAAA) were generated by the splicing overlap extension PCR technique (Ho et al., 1989) , with specially designed primers (Table 2) , to introduce the mutation.
Using Wnt2-pGL3 as a template, two parts of the Wnt2 promoter fragment were generated as PCR fragments, using the forward and reverse primers (for corresponding sites, see above), together with primers GL2 and RV3 (Promega), respectively. Amplifying the two annealed PCR products using primers GL 2 and RV 3 generated the complete mutated fragments. These were then digested with XhoI and HindIII and inserted into similarly digested pGL3-Basic vector, resulting in Wnt2mut1-pGL3 and Wnt2mut2-pGL3.
The Renilla luciferase internal control reporter vector pRL-SV40-d238 with a mutated GATA-binding site (Ho and Strauss, 2004 ) was a kind gift of Clement Ho.
Microarray analysis
Total RNA was extracted from induced P19-CL6 cell cultures using the SV total RNA isolation kit (Promega) according to the manufacturer's instructions. Biological triplicates of induced P19-CL6 cells, cultured on 6 cm dishes, were transfected at day 3 of induction with either empty expression vector pLINK (control) or pLINK-G6 and harvested on day 4 of induction. RNA quality was assessed on an Agilent 2100 bioanalyzer equipped with the RNA LabChip according to manufacturer's instructions. Biotin-labelled cRNA was prepared according to the Affymetrix protocol.
Three Mouse Expression Arrays 430A (Affymentix), each representing aproximatelly 23,000 transcripts, were used for assessment of GATA6 targets. Two 430A arrays were hybridised with cRNA generated from pLINKtransfected cells and one was hybridised with cRNA from pLINK-G6-transfected cells. All sample preparations and hybridisations were performed according to the manufacturer's instructions.
Expression levels of transcripts were analysed using statistical algorithms with the default settings, in the Microarray Analysis Suite 5.0 software (Affymetrix). Data were globally scaled to correct for any small variations in hybridisation efficiency, laser power, etc. Only genes with a change in expression R2-fold (signal log ratio (SLR) %K1.0 or RC1.0) between the arrays were considered.
qPCR analysis
Total RNA was reverse transcribed, using random decamers, with AMV RT (Promega) according to the manufacturer's protocol. Control reactions, omitting AMV RT, were also performed. Relative expression levels of the specific transcripts were quantified by qPCR using fluorescent SYBR Green I technology on the ABI PRISM 7000 HT sequence detection system (Applied Biosystems), and normalised to those of cytoskeletal b-actin. Primers were designed using the Primer Express software (Applied Biosystems) with default settings, applied to mouse cDNA sequences derived from the NCBI web site (http://www.ncbi.nlm.nih.gov), and are shown in Table 2 . Each experiment was repeated in triplicate and assayed at least in duplicate. Validation experiments demonstrated that the efficiencies of the primers were approximately equal and specific for their targets, thus the comparative Ct method was used for relative quantification, as described previously (Winer et al., 1999; Brewer et al., 2005) . Where the relative expression levels of several genes within one sample were analysed, the same threshold Ct was set for all primers.
Whole-mount in situ hybridisation
The mouse GATA6 probe was prepared as previously described (Brewer et al., 1999) . The mouse Wnt2 probe was a 1.1 kb fragment generated by PCR using the primers shown in Table 2 .
This was cloned into pGEM T Easy vector (Promega), linearised with NcoI, and transcribed with SP6 RNA Polymerase (Roche).
Synthesis of dig-11-UTP labelled riboprobes was carried out using the DIG RNA Labeling Kit (SP6/T7) (Roche) according to the manufacturer's instructions. Efficiency of the labelling reaction was checked using a standard dot-blot assay.
Whole-mount in situ hybridisation was carried out on E9.5 mouse embryos based on protocols described previously (Mankoo et al., 2003) . After colour development, embryos were washed in PBT (PBS/0.1% Tween-20) overnight, postfixed overnight in 4% paraformaldehyde, 0.1% glutaraldehyde in PBT. For whole-mount photography, embryos were transferred into PBT. For cryostatsectioning, embryos were equilibrated overnight with 30% sucrose in PBS, embedded in OCT (BDH) and frozen on dry ice. 30 mm sections were cut on a Bright cryostat.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from untransfected and pLINK-G6-transfected Cos7 cells using the NE-PER kit (Pierce), exactly as described by the manufacturer. The complementary single-stranded oligonucleotides (Table 2) were annealed at 1 mM in 100 mM NaCl, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA. Double stranded (ds) oligonucleotides (Wnt2 site 1, Wnt2 site 2 and aG2) were radiolabelled at their 5 0 termini using [g-32 P] dATP (3 kCi/mM) and T4 polynucleotide kinase (Promega). Each 20 ml assay mix contained 20 fmol ds radiolabelled oligonucleotide probe, 4 pmol ds unlabelled competitor oligonucleotide (as necessary), 6 mg protein extract in a buffer comprising 10 mM Tris-HCl pH 7.5, 50 mMKCl, 5 mMMgCl 2 1 mMDTT, 150 mg/ml poly dIdC, 10% glycerol. Reactions were pre-incubated at room temperature for 20 min before the addition of the radiolabelled probe, and subsequently for a further 20 min. DNA-protein complexes were resolved on 6% non-denaturing TBE polyacrylamide gels, containing 10% glycerol, which were vacuum-dried and exposed to X-ray film for autoradiographic detection.
Promoter activity assays
Induced P19-CL6 cells were cultured in 24-well plates (Nunc). For the time course experiment, cells induced at 2 day intervals were co-transfected with 1 mg Wnt2-pGL3 and 1 mg pRL-SV40-d238. For GATA6 transactivation assays, cells were co-transfected at day 3 of induction with 0.5 mg luciferase reporter vector (Wnt2-pGL3, Wnt2mut1-pGL3 or Wnt2mut2-pGL3), together with 0.5 mg pLINK-G6 or pLINK, and 1 mg pRL-SV40-d238. Cells were assayed for luciferase activity using the Dual-Glo Luciferase Assay System (Promega) according to manufacturer's instructions. The firefly luciferase activity, driven by the Wnt2 promoter fragments was normalised to the Renilla luciferase activity, to yield the relative luciferase activity. Each experiment was repeated in triplicate and assayed at least in duplicate.
Bioinformatics
Homologous regions of the Wnt2 promoters of human, chimpanzee, mouse and rat (accession nos. AC002465, AADA01273045, AC068561 and AC087112, respectively) were aligned by using multiple alignment tool AliBee at http://www.genebee.msu.su/services/malign_full.html with the default settings. GATA transcription factor binding sites within these promoter regions were explored with the ConSite tool available at http://mordor.cgb.ki. se/cgi-bin/CONSITE/consite.
